BIK and head and neck squamous cell carcinoma: In head and neck squamous cell carcinoma cells, increased BIK by Bortezomib enhanced cisplatin-induced apoptosis and loss of Bik accelerated murine lymphoma development or rendered lymphoma cells resistant to DNA damaging drugs [34–36].